Tudor Investment Corp ET AL lowered its stake in Ophthotech Corporation (NASDAQ:OPHT) by 49.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,923 shares of the biopharmaceutical company’s stock after selling 33,100 shares during the period. Tudor Investment Corp ET AL owned approximately 0.09% of Ophthotech Corporation worth $124,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in Ophthotech Corporation by 67.7% in the first quarter. SG Americas Securities LLC now owns 50,867 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 20,537 shares during the period. Teachers Advisors LLC boosted its position in Ophthotech Corporation by 6.1% in the fourth quarter. Teachers Advisors LLC now owns 52,243 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 2,999 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Ophthotech Corporation during the first quarter valued at about $345,000. KCG Holdings Inc. acquired a new position in Ophthotech Corporation during the first quarter valued at about $354,000. Finally, Schwab Charles Investment Management Inc. boosted its position in Ophthotech Corporation by 73.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 49,928 shares during the last quarter. Institutional investors and hedge funds own 72.25% of the company’s stock.
Shares of Ophthotech Corporation (OPHT) opened at 2.80 on Friday. The company’s 50 day moving average price is $2.63 and its 200-day moving average price is $3.09. The firm’s market cap is $100.64 million. Ophthotech Corporation has a 1-year low of $2.24 and a 1-year high of $59.99.
Ophthotech Corporation (NASDAQ:OPHT) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.45. The firm had revenue of $1.66 million during the quarter, compared to analyst estimates of $1.38 million. During the same period in the prior year, the business earned ($0.85) EPS. The business’s revenue for the quarter was down 94.1% compared to the same quarter last year. Equities analysts expect that Ophthotech Corporation will post $0.29 EPS for the current fiscal year.
WARNING: “Ophthotech Corporation (OPHT) Shares Sold by Tudor Investment Corp ET AL” was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/19/tudor-investment-corp-et-al-sells-33100-shares-of-ophthotech-corporation-opht-updated-updated.html.
Separately, Zacks Investment Research upgraded Ophthotech Corporation from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Tuesday, May 2nd. Twelve research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Ophthotech Corporation has a consensus rating of “Hold” and an average target price of $54.47.
In other Ophthotech Corporation news, Chairman David R. Guyer sold 17,678 shares of Ophthotech Corporation stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $2.58, for a total value of $45,609.24. Following the sale, the chairman now owns 37,692 shares of the company’s stock, valued at approximately $97,245.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 34,609 shares of company stock worth $89,249 in the last three months. Company insiders own 2.00% of the company’s stock.
Ophthotech Corporation Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with MarketBeat.com's FREE daily email newsletter.